A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
Public ClinicalTrials.gov record NCT02420821. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.
Study identification
- NCT ID
- NCT02420821
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 915 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2015 (Actual)
- Primary completion
- Feb 14, 2020 (Actual)
- Completion
- Dec 13, 2021 (Actual)
- Last update posted
- Jan 30, 2023
2015 – 2021
United States locations
- U.S. sites
- 28
- U.S. states
- 18
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| University of California at Irvine Medical Center; Department of Oncology | Orange | California | 92868 | — |
| University of California | San Francisco | California | 94158 | — |
| University of Colorado; Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer Center; Medical Oncology | Boulder | Colorado | 80303 | — |
| Georgetown U; Lombardi Comp Can | Washington D.C. | District of Columbia | 20016-1468 | — |
| Lynn Cancer Institute/Boca Raton Regional Hospital | Boca Raton | Florida | 33486 | — |
| Florida Cancer Specialists - Port Charlotte | Port Charlotte | Florida | 33980 | — |
| Florida Cancer Specialist, North Region | St. Petersburg | Florida | 33705 | — |
| Piedmont Cancer Institute, PC | Atlanta | Georgia | 30318 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Inst. | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Comprehensive Cancer Centers of Nevada - Eastern Avenue | Las Vegas | Nevada | 89169 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| New York Oncology Hematology,P.C.-Albany | Albany | New York | 12208 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | — |
| Cleveland Clinic Foundation; Taussig Cancer Center | Cleveland | Ohio | 44195 | — |
| Northwest Cancer Specialists, P.C. | Tigard | Oregon | 97223 | — |
| SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Cancer Center and Research Institute | Nashville | Tennessee | 37203 | — |
| Vanderbilt Univ Medical Ctr | Nashville | Tennessee | 37232 | — |
| Texas Oncology-Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Oncology and Hematology Associates of SW Virginia-Raonoke | Roanoke | Virginia | 24014 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 126 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02420821, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2023 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02420821 live on ClinicalTrials.gov.